This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephen R. Preblud, MD

JAMA. 1985;254(2):253-256.

Abstract
At the time of licensure in 1969, available data indicated that rubella vaccines were safe, noncommunicable, and effective. Since vaccine virus could cross the placenta and infect the fetus, cautious use of the vaccines in childbearing-age women was recommended. Over the past 15 years, additional information about the vaccines has been accumulated. This article provides an update of data on (1) the risk and degree of joint symptoms following vaccination and revaccination, (2) the duration of vaccine-induced immunity, (3) the protective effect of low levels of vaccine-induced antibody, and (4) the risks to the fetus following maternal vaccination. The data support continued vaccination of all young children as well as increased efforts to vaccinate susceptible adolescents and young adults, especially women. Only by more effective vaccination of the latter can elimination of congenital rubella syndrome be hastened.

(JAMA 1985;254:253-256)

Author Affiliations
From the Division of Immunization, Center for Prevention Services, Centers for Disease Control, Atlanta.

Footnotes
Read in part before the 19th Immunization Conference, Boston, May 22, 1984.

Reprint requests to Technical Information Services, Center for Prevention Services, Centers for Disease Control, Atlanta, GA 30333.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Profile of Mothers Giving Birth to Infants With Congenital Rubella Syndrome: An Assessment of Risk Factors
Kaplan et al.
Arch Pediatr Adolesc Med 1990;144:118-123.
ABSTRACT